Regulus Therapeutics
RGLS
#7200
Rank
C$0.81 B
Marketcap
C$11.70
Share price
0.00%
Change (1 day)
446.28%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -C$66.2 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -C$66.25 Million a decrease over its 2023 earnings that were of -C$42.21 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -C$66.2 Million-0.07%
2024 -C$66.25 Million56.97%
2023 -C$42.21 Million6.51%
2022 -C$39.63 Million2.53%
2021 -C$38.65 Million93.59%
2020 -C$19.97 Million-15.41%
2019 -C$23.6 Million-64.46%
2018 -C$66.4 Million-33.26%
2017 -C$99.49 Million-13.98%
2016 -C$0.12 Billion44.77%
2015 -C$79.89 Million-1.63%
2014 -C$81.22 Million203.6%
2013 -C$26.76 Million8.65%
2012 -C$24.63 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
C$11.16 B-16,520.40%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
C$0.63 B-1,038.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$16.24 B-23,992.56%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
C$21.63 B-31,913.87%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
C$10.25 B-15,184.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-C$0.16 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-C$0.17 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
C$1.75 B-2,675.32%๐Ÿ‡บ๐Ÿ‡ธ USA